Ceo
CurrentCardioRenal Systems® is the developer of the only clinically validated solution for preventing Acute Kidney Injury (AKI) in common hospitalizations from cardiac surgery and interventional cardiology to ICU. Its next generation device for fluid management and AKI prevention is CE approved with growing sales throughout EMEA and was granted breakthrough designation by the FDA. AKI prevention is a major unmet medical need and a $10B+ addressable market.In the UK based KIDNEY Study, a 220-patient randomized, controlled clinical trial, RenalGuard Therapy® demonstrated a 52% reduction in AKI compared to the standard of care. In the 780K annual cardiac surgery procedures in the US & EMEA, 80% of patients are at risk, and 30% of patients go on to suffer from AKI. There is also increasing awareness of sepsis associated AKI in the ICU, where initial POC studies have shown promising results.